Mandate

Vinge advises Main Capital and Alfa eCare in connection with the acquisition of Selfpoint

The Alfa eCare group is a recognized and rapidly growing software provider within the e-health sector that offers solutions to both private and public healthcare providers in the Nordics.

Selfpoint Sverige AB was founded in 2015 and provides a comprehensive low-code platform for workflow and process management solutions for the Swedish welfare market. The company serves over 40 customers with a strong presence in the public sector. The flexible low-code platform enables customers to digitize workflows and processes across the value chain towards citizens and care givers. The acquisition of Selfpoint is the seventh acquisition by the Alfa eCare group since Main Capital became majority owners of the group in 2020.

Vinge’s team advising Main Capital and Alfa eCare mainly consisted of Filip Öhrner, Per Kling, Robin Fagerström (M&A), Sara Passandideh (Employment), Martin Boström (Commercial Agreements) Lisa Hörnqvist (IT and GDPR), Rebecka Målquist, Johan Gavelin (IP) and Emelie Schoning (project assistant).

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025